


El Salvador - BCG

SLV - BCG




Description:

- 1997: Legacy estimate.
- 1998: Estimate based on reported data.
- 1999: Estimate based on interpolation between 1998 and 2000. Reported data not accepted due to a decline from 100 percent to 72 percent with a subsequent increase to 99 percent.
- 2000: Estimate based on reported data.
- 2001: Estimate based on reported data.
- 2002: Estimate based on reported data. 98 percent survey results supports reported data of 92 percent.
- 2003: Estimate based on reported data.
- 2004: Estimate based on reported data.
- 2005: Estimate based on reported data.
- 2006: Estimate based on reported data.
- 2007: Estimate based on reported data. 98 percent survey results supports reported data of 100 percent.
- 2008: Estimate based on reported data.
- 2009: Estimate based on reported data. Two months shortage of BCG vaccine reported.
- 2010: Estimate based on reported data.

	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
Estimate	95	99	99	99	92	92	91	94	84	93	99	99	87	91
Official	95	100	72	99	92	92	91	94	84	93	100	99	87	91
Administrative	95	100	72	99	92	92	91	94	84	93	100	99	87	91
Survey	96	NA	NA	NA	NA	98	NA	NA	NA	NA	98	NA	NA	NA

El Salvador - DTP1

SLV - DTP1




Description:

- 1997: Legacy estimate.
- 1998: No accepted DTP1 data. Estimate based on DTP3 coverage of 100. Current estimate of 99 percent changed from previous revision value of 98 percent.
- 1999: No accepted DTP1 data. Estimate based on DTP3 coverage of 94.
- 2000: DTP1 coverage estimated based on DTP3 coverage of 99. Current estimate of 99 percent changed from previous revision value of 98 percent.
- 2001: DTP1 coverage estimated based on DTP3 coverage of 92.
- 2002: DTP1 coverage estimated based on DTP3 coverage of 81. Current estimate of 93 percent changed from previous revision value of 87 percent.
- 2003: DTP1 coverage estimated based on DTP3 coverage of 94. Current estimate of 98 percent changed from previous revision value of 95 percent.
- 2004: DTP1 coverage estimated based on DTP3 coverage of 90. Current estimate of 96 percent changed from previous revision value of 92 percent.
- 2005: DTP1 coverage estimated based on DTP3 coverage of 89. Current estimate of 96 percent changed from previous revision value of 93 percent.
- 2006: DTP1 coverage estimated based on DTP3 coverage of 96.
- 2007: No accepted DTP1 data. Estimate based on DTP3 coverage of 100. Reported data of 111 percent greater than 100 percent. Reported data not accepted due to an increase from 79 percent to 111 percent with a subsequent decrease to 94 percent. Current estimate of 99 percent changed from previous revision value of 98 percent.
- 2008: DTP1 coverage estimated based on DTP3 coverage of 98.
- 2009: DTP1 coverage estimated based on DTP3 coverage of 91. Current estimate of 97 percent changed from previous revision value of 99 percent.
- 2010: DTP1 coverage estimated based on DTP3 coverage of 92.

	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
Estimate	98	99	98	99	97	93	98	96	96	98	99	99	97	97
Official	NA	NA	NA	87	NA	76	84	81	82	79	111	94	90	90
Administrative	NA	NA	NA	87	77	76	84	81	82	79	111	94	90	90
Survey	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

El Salvador - DTP3

SLV - DTP3



Description:

1997: Legacy estimate.

1998: Estimate based on reported data.

1999: Estimate based on reported data.

2000: Estimate based on reported data.

2001: Estimate based on reported data.

2002: Estimate based on reported data. 89 percent survey results supports reported data of 81 percent. na

2003: Estimate based on reported data.

2004: Estimate based on reported data.

2005: Estimate based on reported data.

2006: Estimate based on reported data.

2007: Estimate based on reported data. 96 percent survey results supports reported data of 100 percent.

2008: Estimate based on reported data.


2009: Estimate based on reported data.

2010: Estimate based on reported data.

	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
Estimate	97	99	94	99	92	81	94	90	89	96	99	98	91	92
Official	97	100	94	99	92	81	94	90	89	96	100	98	91	92
Administrative	97	100	94	99	92	81	94	90	89	96	100	98	91	92
Survey	86	NA	NA	NA	NA	89	NA	NA	NA	NA	96	NA	NA	NA

El Salvador - Pol3

SLV - Pol3



Description:

1997: Legacy estimate.

1998: Estimate based on reported data.

1999: Estimate based on reported data.

2000: Estimate based on reported data.

2001: Estimate based on reported data.

2002: Estimate based on reported data. 83 percent survey results supports reported data of 81 percent. na

2003: Estimate based on reported data.

2004: Estimate based on reported data.

2005: Estimate based on reported data.

2006: Estimate based on reported data.

2007: Estimate based on reported data. 96 percent survey results supports reported data of 100 percent.

2008: Estimate based on reported data.


2009: Estimate based on reported data.

2010: Estimate based on reported data.

	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
Estimate	97	99	92	98	94	81	93	90	89	96	99	98	91	92
Official	97	99	92	98	94	81	93	90	89	96	100	98	91	92
Administrative	97	99	92	98	94	81	93	90	89	96	100	98	91	92
Survey	86	NA	NA	NA	NA	83	NA	NA	NA	NA	96	NA	NA	NA

El Salvador - MCV

SLV - MCV




Description:

- 1997: Legacy estimate.
- 1998: Estimate based on reported data.
- 1999: Estimate based on reported data.
- 2000: Estimate based on reported data.
- 2001: Estimate based on interpolation between 2000 and 2002. Reported data not accepted due to a decline from 97 percent to 82 percent with a subsequent increase to 93 percent.
- 2002: Estimate based on reported data. Survey not accepted. Measles vaccination is recommend between 12-23 months of age. Survey cohort underestimates coverage.
- 2003: Estimate based on reported data.
- 2004: Estimate based on reported data.
- 2005: Estimate based on reported data.
- 2006: Estimate based on reported data.
- 2007: Estimate based on reported data. Survey not accepted. Measles vaccination is recommend between 12-23 months of age. Survey cohort underestimates coverage.
- 2008: Estimate based on reported data.
- 2009: Estimate based on reported data.
- 2010: Estimate based on reported data.

	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
Estimate	98	99	94	97	95	93	90	93	99	98	99	95	95	92
Official	98	99	94	97	82	93	90	93	99	98	100	95	95	92
Administrative	98	99	94	97	82	93	90	93	99	98	100	95	95	92
Survey	86	NA	NA	NA	NA	80	NA	NA	NA	NA	87	NA	NA	NA

El Salvador - HepB3

SLV - HepB3



Description:

1999: HepB introduced in 1999.

2000: Estimate based on reported data. Introduction of HepB vaccine, supply not stable.

2001: Estimate based on reported data.

2002: Estimate based on reported data. Vaccine presentation changed to DTP-HepB-Hib.

2003: Estimate based on reported data.

2004: Estimate based on reported data.

2005: Estimate based on reported data.

2006: Estimate based on reported data.

2007: Estimate based on reported data. 96 percent survey results supports reported data of 100 percent.

2008: Estimate based on reported data.


2009: Estimate based on reported data.

2010: Estimate based on reported data.

	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
Estimate	NA	NA	1	99	75	81	94	90	89	96	99	98	91	92
Official	NA	NA	1	NA	NA	81	94	90	89	96	100	98	91	92
Administrative	NA	NA	NA	99	75	81	94	90	89	96	100	98	91	92
Survey	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	96	NA	NA	NA

El Salvador - Hib3

SLV - Hib3




Description:

- 2002: Estimate based on reported data. Hib introduced in 2002 Vaccine presentation is DTP-HepB-Hib.
- 2003: Estimate based on reported data.
- 2004: Estimate based on reported data.
- 2005: Estimate based on reported data.
- 2006: Estimate based on reported data.
- 2007: Estimate based on reported data. 96 percent survey results supports reported data of 100 percent.
- 2008: Estimate based on reported data.
- 2009: Estimate based on reported data.
- 2010: Estimate based on reported data.

	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
Estimate	NA	NA	NA	NA	NA	81	94	90	89	96	99	98	91	92
Official	NA	NA	NA	NA	NA	81	94	90	89	96	100	98	91	92
Administrative	NA	NA	NA	NA	NA	81	94	90	89	96	100	98	91	92
Survey	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	96	NA	NA	NA

El Salvador - RotaC

SLV - RotaC




Description:

- 2006: Estimate based on reported data. Rota introduced in 2006
- 2007: Estimate based on reported data.
- 2008: Estimate based on reported data.
- 2009: Estimate based on reported data. Three months shortage of rotavirus vaccine reported.
- 2010: Estimate based on reported data.

	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
Estimate	NA	NA	NA	NA	NA	NA	NA	NA	NA	25	78	83	61	92
Official	NA	NA	NA	NA	NA	NA	NA	NA	NA	25	78	83	61	92
Administrative	NA	NA	NA	NA	NA	NA	NA	NA	NA	25	78	83	61	92
Survey	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

El Salvador - PcV3

SLV - PcV3



Description:

2010: Estimate based on reported data. Pneumococcal conjugate vaccine introduced in 2010.

	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
Estimate	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	59
Official	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	59
Administrative	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	59
Survey	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

El Salvador - survey details

2007 Encuesta Nacional de Salud Familiar FESAL 2008

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Cards seen
BCG	Card or History	98	12-23 m	865	77
BCG	C or H <12 months	98	12-23 m	865	77
DTP3	Card or History	96	12-23 m	865	77
DTP3	C or H <12 months	85	12-23 m	865	77
HepB3	Card or History	96	12-23 m	865	77
HepB3	C or H <12 months	85	12-23 m	865	77
Hib3	Card or History	96	12-23 m	865	77
Hib3	C or H <12 months	85	12-23 m	865	77
MCV	Card or History	87	12-23 m	865	77
Pol3	C or H <12 months	84	12-23 m	865	77
Pol3	Card or History	96	12-23 m	865	77

2002 Encuesta Nacional de Salud Familiar de 2002-2003 (FESAL)

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Cards seen
BCG	Card or History	98	12-23 m	4106	71
BCG	Card <12 months	96	12-23 m	4106	71
BCG	Card	96	12-23 m	4106	71
BCG	C or H <12 months	95	12-23 m	4106	71
DTP3	C or H <12 months	72	12-23 m	3751	71
DTP3	Card	92	12-23 m	3751	71
DTP3	Card <12 months	74	12-23 m	3751	71
DTP3	Card or History	89	12-23 m	3751	71

MCV	Card	84	12-23 m	3408	71
MCV	Card or History	80	12-23 m	3408	71
Pol3	C or H <12 months	59	12-23 m	3751	71
Pol3	Card <12 months	56	12-23 m	3751	71
Pol3	Card or History	83	12-23 m	3751	71
Pol3	Card	86	12-23 m	3751	71

1997 Encuesta Nacional de Salud Familiar FESAL-98

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Cards seen
BCG	C or H <12 months	88	12-23 m	5155	60
BCG	Card	92	12-23 m	5155	60
BCG	Card <12 months	92	12-23 m	5155	60
BCG	Card or History	96	12-23 m	5155	60
DTP3	C or H <12 months	95	12-23 m	5155	60
DTP3	Card or History	86	12-23 m	5155	60
DTP3	Card <12 months	72	12-23 m	5155	60
DTP3	Card	65	12-23 m	5155	60
MCV	Card or History	86	12-23 m	5155	60
MCV	Card <12 months	59	12-23 m	5155	60
MCV	Card	55	12-23 m	5155	60
MCV	C or H <12 months	92	12-23 m	5155	60
Pol3	C or H <12 months	95	12-23 m	5155	60
Pol3	Card	65	12-23 m	5155	60
Pol3	Card or History	86	12-23 m	5155	60
Pol3	Card <12 months	72	12-23 m	5155	60

Further information and estimates for 1980-1996 are available at:

http://www.childinfo.org/immunization_countryreports.html

http://www.who.int/immunization_monitoring/routine/immunization_coverage/en/index4.html

El Salvador

WHO/UNICEF Estimates of Protection at Birth (PAB) against tetanus

In countries where tetanus is recommended for girls and women coverage is usually reported as "TT2+", i.e. the proportion of (pregnant) women who have received their second or superior TT dose in a given year. TT2 + coverage, however, can under-represent the actual proportion of births that are protected against tetanus as it does not include women who have previously received protective doses, women who received one dose without documentation of previous doses, and women who received doses in TT (or Td) supplemental immunization activities (SIA). In addition, girls who have received DTP in their childhood and are entering childbearing age, may be protected with TT booster doses.

WHO and UNICEF have developed a model that takes into account the above scenarios, and calculates the proportion of births in a given year that can be considered as having been protected against tetanus - "Protection at Birth".

In this model, annual cohorts of women are followed from infancy through their life. A proportion receive DTP in infancy (estimated based on the WHO-UNICEF estimates of DTP3 coverage). In addition some of these women also receive TT through routine services when they are pregnant and may also receive TT during SIAs. The model also adjusts reported data, taking into account coverage patterns in other years, and/or results available through surveys. The duration of protection is then calculated, based on WHO estimates of the duration of protection by doses ever received. The proportion of births that are protected against tetanus as a result of maternal immunization reflects the tetanus immunization received by the mother throughout her life rather than simply the TT immunizations received during the current pregnancy.

Year	PAB coverage estimate (%)
1997	74
1998	77
1999	80
2000	83
2001	85
2002	87
2003	90
2004	93
2005	92
2006	91
2007	87
2008	87
2009	87
2010	88

¹ This model is described in: Griffiths U., Wolfson L., Quddus A., Younus M., Hafiz R.. Incremental cost-effectiveness of supplementary immunization activities to prevent neo-natal tetanus in Pakistan. Bulletin of the World Health Organization 2004; 82:643-651.